Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced nonsquamous non-small-cell lung cancers
    Journal Article

    Hellmann, M. D.; Sturm, I.; Trnkova, Z. J.; Lettieri, J.; Diefenbach, K.; Rizvi, N. A.; Gettinger, S. N.
    Clinical Lung Cancer (2015)

    Fulltext@MSK | Save
  • Genetics and immunology: Reinvigorated
    Journal Article

    Snyder, A.; Makarov, V.; Hellmann, M.; Rizvi, N.; Merghoub, T.; Wolchok, J. D.; Chan, T. A.
    OncoImmunology (2015)

    Fulltext@MSK | Save
  • Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001
    Meeting Abstract

    Rizvi, N. A.; Garon, E. B.; Leighl, N.; Hellmann, M. D.; Patnaik, A.; Gandhi, L.; Eder, J. P.; Rangwala, R. A.; Lubiniecki, G.; Zhang, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression
    Meeting Abstract

    Gettinger, S. N.; Hellmann, M. D.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q. M.; Goldman, J. W.; Juergens, R. A.; Borghaei, H.; Ready, N.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
    Journal Article

    Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas
    Journal Article

    Yu, H. A.; Sima, C. S.; Hellmann, M. D.; Naidoo, J.; Busby, N.; Rodriguez, K.; Riely, G. J.; Kris, M. G.
    Cancer (2015)

    Fulltext@MSK | Save
  • Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    Journal Article

    Rizvi, N. A.; Hellmann, M. D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J. J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T. S. ; more...
    Science (2015)

    Fulltext@MSK | Save
  • Pembrolizumab for the treatment of non-small-cell lung cancer
    Journal Article

    Garon, E. B.; Rizvi, N. A.; Hui, R.; Leighl, N.; Balmanoukian, A. S.; Eder, J. P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Opportunistic infections in patients treated with immunotherapy for cancer
    Journal Article

    Kyi, C.; Hellmann, M. D.; Wolchok, J. D.; Chapman, P. B.; Postow, M. A.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save